Developer docs
API playgroundTry for free, no card

Search company profiles

Curetopia

Full company profile

uuid0003wz8

Namestring
Curetopia
Legal namestring
Curetopia Association
Websiteurl
curetopia.xyz
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Curetopia is a Swiss non-profit association (verein) and the first biotech Decentralized Autonomous Organization (BioDAO) focused on eradicating rare genetic diseases through decentralized science. Founded in 2024 by Ethan O. Perlstein, Ph.D. (also founder of Perlara PBC), the organization enables on-chain governance of rare disease research by patient communities, scientists, and DeSci supporters via the $CURES governance token issued on Solana (100M total supply). Its core scientific platform leverages Saccharomyces cerevisiae yeast as a model organism for high-throughput drug repurposing, using genetically engineered 'yeast-patient avatars' that carry patient-specific mutations to screen an 8,400-compound TargetMol library of FDA-approved drugs, nutraceuticals, and OTC supplements. Curetopia has prospectively identified nearly 800 inherited metabolic diseases as addressable through this yeast-based approach, with a 2025 roadmap to scale from one pilot disease to 60.

Curetopia's business model operates across multiple potential revenue streams: direct-to-consumer commercial spinouts of nutraceutical combination therapies (modeled on VitaDAO's Blueprint), biopharma licensing of drug repurposing candidates and IP-NFTs, mission-aligned investments in allied rare disease platforms (such as Unravel Biosciences), and potential Priority Review Voucher value of approximately $150M contingent on US regulatory reauthorization. The organization employs 1-to-N decentralized observational clinical trials as a low-cost alternative to traditional institutional studies, with anti-shelving smart contract provisions designed to prevent promising programs from being abandoned.

The organization serves three primary customer segments: rare disease patient communities and families seeking research funding, researchers and clinicians needing capital for underserved programs, and the DeSci/crypto community seeking transparent, mission-driven investment vehicles. Curetopia raised $1.77 million through community crowdfunding in December 2024, attracting over 1,000 participants to fund its pilot AARS2 deficiency project. Core operational partnerships include Perlara PBC (yeast screening laboratory), BIO Protocol (DeSci infrastructure), CombinedBRAIN (120+ neurodevelopmental disorder affiliates), and the CureARS Foundation (AARS2 patient community).

Short descriptiontext

Curetopia is a Swiss BioDAO that funds rare disease drug repurposing research through community-governed token-based decision-making on Solana, using yeast-powered screening of 8,400 compounds to identify repurposing candidates for inherited metabolic diseases affecting underserved patient communities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug repurposing, rare disease research, decentralized science, biotech governance, patient communities
Industry3 codes
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJAMAC
Public Health Financing, Budgeting & Grants Management
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Research
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Direct-to-Consumer Commercial Spinouts
TypeHardware Sales
Description

Revenue generated from selling proprietary combination therapies (nutraceutical stacks) directly to consumers via commercial spinouts, similar to VitaDAO's Blueprint model. Initial focus on inherited metabolic diseases where drug repurposing screens consistently yield nutraceutical candidates.

curetopia.xyz
2Biopharma Licensing Deals
TypeLicensing Royalties
Description

Income from licensing drug repurposing candidates, IP-NFTs, and therapeutic modalities to biopharma companies. Rare disease research funded by Curetopia results in IP ownership rights that may be monetized through B2B licensing arrangements.

curetopia.xyz
3Mission-Aligned Investments
TypeManaged Services
Description

Income from strategic investments in allied rare disease platform companies or projects, such as Unravel Biosciences, capturing upside potential in partner organizations.

curetopia.xyz
4Priority Review Voucher (PRV) Value
TypeLicensing Royalties
Description

Potential $150M market incentive from PRV reauthorization for developing medicines for rare pediatric diseases, representing a long-term value creation pathway contingent on US regulatory reauthorization.

curetopia.xyz
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1No product/service tiers - DAO governance token only
ModelOtherBilling cadenceMulti-year contract
Notes

Curetopia operates as a non-profit DAO. There are no commercial product or service tiers. $CURES tokens are governance tokens with utility for voting on DAO proposals. No public pricing for research participation or partnership arrangements.

curetopia.xyz
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Curetopia operates as a BioDAO (Biotech Decentralized Autonomous Organization) structured as a Swiss non-profit association that funds and conducts rare disease research through on-chain governance. The organization uses yeast-powered drug repurposing screens (Saccharomyces cerevisiae model organisms) against an 8,400-compound library to identify existing drugs, nutraceuticals, and supplements with therapeutic potential for rare genetic diseases. Community members govern research direction and IP outcomes via the $CURES governance token on Solana.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 95% of 10,000+ rare diseases have no approved treatment, representing massive unmet need
+4 more records
Product overview1 text field

Curetopia is a BioDAO (Biotech Decentralized Autonomous Organization) structured as a Swiss non-profit association (verein) that combines decentralized governance with scientific research to eradicate rare diseases. The platform consists of the Curetopia DAO Platform (governance infrastructure), the $CURES token (utility and governance token enabling community participation), and the Yeast Drug Repurposing Platform (scientific research infrastructure operated by partner laboratory Perlara). The AARS2 Drug Repurposing Project serves as Curetopia's pilot research initiative. Additional offerings include the Curetopia Journal (editorial content platform) and Community Auction (token distribution mechanism). The platform enables patients, families, scientists, and supporters to collectively fund, govern, and advance rare disease research through on-chain voting and token-based governance.

Product and service4 records
1Curetopia DAO Platform
CategoryGovernance Platform
Description

On-chain governance platform enabling rare disease patient communities, scientists, and DeSci enthusiasts to vote on research proposals, funding allocations, and intellectual property decisions. Token holders control the fate of IP created from community-sponsored research through transparent, community-driven processes.

2$CURES Token
CategoryGovernance Token
Description

Utility and governance token with a total supply of 100,000,000 tokens. Enables community members to vote on DAO actions and participate in research governance. Allocates 20% to core team (with vesting), 40% to treasury reserves, 15% to community auction, 10% to future token sales, 7% to service providers, 7% to community incentives, and 1% to airdrops.

3Yeast Drug Repurposing Platform
CategoryDrug Repurposing Research
Description

Scientific research platform that leverages Saccharomyces cerevisiae (baker's yeast) as a model organism for high-throughput drug repurposing screens. Partner laboratory Perlara conducts screening against an 8,400-compound TargetMol library to identify existing drugs, nutraceuticals, and supplements with therapeutic potential for rare genetic diseases. Has prospectively identified nearly 800 inherited metabolic diseases (8% of all known rare diseases) caused by loss-of-function mutations in evolutionarily conserved genes.

4AARS2 Drug Repurposing Project
CategoryResearch Project
Description

Pilot research project focused on identifying drug repurposing candidates for AARS2 deficiency (Progressive Leukoencephalopathy with Ovarian Failure) using yeast-patient avatars. Screens approximately 8,500 repurposable compounds to find treatments for rare kiddos affected by this mitochondrial disease. Funded through $1.77 million in community crowdfunding.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1CureARS Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-09
Description

CureARS Foundation is the patient community organization for the AARS2 project. The foundation represents families affected by aminoacyl-tRNA synthetase (ARS) diseases and is ready to spread word about research results to their micro-communities and organize rapid 1-to-N clinical testing in affected children.

curetopia.xyz
Strategic tierCoreTypeTechnology or Integration
Description

Perlara PBC is Curetopia's primary research partner and yeast-screening laboratory. Founded in 2014 as the world's first biotech Public Benefit Corporation, Perlara conducts high-throughput drug repurposing screens using yeast-patient avatars. Curetopia's AARS2 project is conducted at Perlara's laboratory in Alameda, CA, and builds on Perlara's decade of experience with yeast-powered drug discovery.

Strategic tierCoreTypeGTM or Marketing Partner
Description

BIO Protocol is a DeSci Funding & Liquidity Protocol that provides support with tokenomics design, DAO formation, legal/regulatory advisory, and Web3 technology infrastructure. BIO received 7% of $CURES token supply as service provider compensation. BIO Protocol's launchpad hosted Curetopia's community auction on Solana.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

CombinedBRAIN (CB) is an umbrella foundation with 120+ neurodevelopmental disorder (NDD) rare disease community affiliates that share common research infrastructure including a biobank and a network of responsive clinicians willing to test drug repurposing candidates in collaboration with affected families. Curetopia is in active discussions to scale up drug repurposing for all rare disease communities through this partnership.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Unravel Biosciences is a Boston-based company that has developed rareSHIFT, a fully decentralized, direct-to-patient drug repurposing protocol involving at-home nasal swab collection, RNAseq gene expression analysis, and computational screening for drug repurposing candidates. Curetopia views Unravel as an ideal investment opportunity and codevelopment partner for rare disease programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Maggie's Pearl is a joint venture between Perlara and a PMM2-CDG family foundation dedicated to advancing epalrestat (discovered through drug repurposing screens) to the global market. The venture culminated in a pivotal clinical trial in pediatric PMM2-CDG patients. This represents a model for how Curetopia-funded research could be commercialized.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer longevity BioDAO using a $VITA governance token on Ethereum to fund and govern early-stage research, with on-chain IP via Molecule. The most established direct analogue to Curetopia's BioDAO model, differing by therapeutic area.

TypeDirect peer
Description

Boston-based rare disease drug repurposing company with a decentralized, direct-to-patient rareSHIFT protocol; Curetopia lists Unravel as a codevelopment partner and investment target, making it a tightly overlapping peer.

TypeOthers
Description

Umbrella foundation for 120+ neurodevelopmental-disorder rare disease community affiliates that shares biobank and clinician infrastructure with Curetopia; functions as a community-distribution partner rather than a competitor, but operates in the same rare-disease space.

TypeDirect peer
Description

DeSci platform that pioneered IP-NFTs and on-chain research funding; Curetopia is already a Molecule ecosystem partner, and the two share the same IP-tokenization infrastructure.

5Biovista
TypeDirect peer
Description

Commercial drug repurposing firm using systematic biological-data approaches to find new indications, including in rare diseases; comparable to Curetopia on the core repurposing thesis but operates as a traditional B2B services company.

TypeDirect peer
Description

AI-driven drug repurposing company focused on rare diseases; comparable in mission and in repurposing methodology, though Curetopia uses yeast models and decentralized governance while Healx uses in-silico AI and traditional venture backing.

TypeDirect peer
Description

DeSci launchpad and liquidity protocol that incubated Curetopia and hosted its community auction. Closely comparable as the funding-and-launch infrastructure layer for BioDAOs.

TypeDirect peer
Description

DeSci DAO funding longevity and age-related disease research via IP-NFTs and token-based governance; another direct structural analogue operating in the BioDAO category.

TypeDirect peer
Description

BioDAO focused on women's health and longevity research using a token-governed funding model; structurally identical to Curetopia (BioDAO + on-chain research funding) but with a different therapeutic focus.

TypeBroad incumbent
Description

Curetopia's core research partner and laboratory operator; founded by the same individual, it is the world's first biotech Public Benefit Corporation and runs the yeast-powered drug repurposing platform that Curetopia's pipeline depends on.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curetopia

Rare Disease Researchcuretopia.xyz

Curetopia is a Swiss BioDAO that funds rare disease drug repurposing research through community-governed token-based decision-making on Solana, using yeast-powered screening of 8,400 compounds to identify repurposing candidates for inherited metabolic diseases affecting underserved patient communities.

What Curetopia does

Curetopia is a Swiss non-profit association (verein) and the first biotech Decentralized Autonomous Organization (BioDAO) focused on eradicating rare genetic diseases through decentralized science. Founded in 2024 by Ethan O. Perlstein, Ph.D. (also founder of Perlara PBC), the organization enables on-chain governance of rare disease research by patient communities, scientists, and DeSci supporters via the $CURES governance token issued on Solana (100M total supply). Its core scientific platform leverages Saccharomyces cerevisiae yeast as a model organism for high-throughput drug repurposing, using genetically engineered 'yeast-patient avatars' that carry patient-specific mutations to screen an 8,400-compound TargetMol library of FDA-approved drugs, nutraceuticals, and OTC supplements. Curetopia has prospectively identified nearly 800 inherited metabolic diseases as addressable through this yeast-based approach, with a 2025 roadmap to scale from one pilot disease to 60.

Curetopia's business model operates across multiple potential revenue streams: direct-to-consumer commercial spinouts of nutraceutical combination therapies (modeled on VitaDAO's Blueprint), biopharma licensing of drug repurposing candidates and IP-NFTs, mission-aligned investments in allied rare disease platforms (such as Unravel Biosciences), and potential Priority Review Voucher value of approximately $150M contingent on US regulatory reauthorization. The organization employs 1-to-N decentralized observational clinical trials as a low-cost alternative to traditional institutional studies, with anti-shelving smart contract provisions designed to prevent promising programs from being abandoned.

The organization serves three primary customer segments: rare disease patient communities and families seeking research funding, researchers and clinicians needing capital for underserved programs, and the DeSci/crypto community seeking transparent, mission-driven investment vehicles. Curetopia raised $1.77 million through community crowdfunding in December 2024, attracting over 1,000 participants to fund its pilot AARS2 deficiency project. Core operational partnerships include Perlara PBC (yeast screening laboratory), BIO Protocol (DeSci infrastructure), CombinedBRAIN (120+ neurodevelopmental disorder affiliates), and the CureARS Foundation (AARS2 patient community).

Curetopia firmographics

Firmographics
Name
Curetopia
Legal name
Curetopia Association
Website
https://curetopia.xyz
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Curetopia is a Swiss BioDAO that funds rare disease drug repurposing research through community-governed token-based decision-making on Solana, using yeast-powered screening of 8,400 compounds to identify repurposing candidates for inherited metabolic diseases affecting underserved patient communities.
Ownership category
akta.pro rank

Curetopia industry classification

Industry
Product category
Rare Disease Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Voluntary Health Organizations (813212)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYHLAJAMAC
Public Health Financing, Budgeting & Grants Management

Keywords

  • Drug repurposing
  • Rare disease research
  • Decentralized science
  • Biotech governance
  • Patient communities

Where Curetopia is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Curetopia business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Direct-to-Consumer Commercial Spinouts: Revenue generated from selling proprietary combination therapies (nutraceutical stacks) directly to consumers via commercial spinouts, similar to VitaDAO's Blueprint model. Initial focus on inherited metabolic diseases where drug repurposing screens consistently yield nutraceutical candidates.
  2. Biopharma Licensing Deals: Income from licensing drug repurposing candidates, IP-NFTs, and therapeutic modalities to biopharma companies. Rare disease research funded by Curetopia results in IP ownership rights that may be monetized through B2B licensing arrangements.
  3. Mission-Aligned Investments: Income from strategic investments in allied rare disease platform companies or projects, such as Unravel Biosciences, capturing upside potential in partner organizations.
  4. Priority Review Voucher (PRV) Value: Potential $150M market incentive from PRV reauthorization for developing medicines for rare pediatric diseases, representing a long-term value creation pathway contingent on US regulatory reauthorization.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNo product/service tiers - DAO governance token only

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Curetopia product offering

Product offering

Core offering

Curetopia operates as a BioDAO (Biotech Decentralized Autonomous Organization) structured as a Swiss non-profit association that funds and conducts rare disease research through on-chain governance. The organization uses yeast-powered drug repurposing screens (Saccharomyces cerevisiae model organisms) against an 8,400-compound library to identify existing drugs, nutraceuticals, and supplements with therapeutic potential for rare genetic diseases. Community members govern research direction and IP outcomes via the $CURES governance token on Solana.

Product overview

Curetopia is a BioDAO (Biotech Decentralized Autonomous Organization) structured as a Swiss non-profit association (verein) that combines decentralized governance with scientific research to eradicate rare diseases. The platform consists of the Curetopia DAO Platform (governance infrastructure), the $CURES token (utility and governance token enabling community participation), and the Yeast Drug Repurposing Platform (scientific research infrastructure operated by partner laboratory Perlara). The AARS2 Drug Repurposing Project serves as Curetopia's pilot research initiative. Additional offerings include the Curetopia Journal (editorial content platform) and Community Auction (token distribution mechanism). The platform enables patients, families, scientists, and supporters to collectively fund, govern, and advance rare disease research through on-chain voting and token-based governance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Curetopia DAO Platform On-chain governance platform enabling rare disease patient communities, scientists, and DeSci enthusiasts to vote on research proposals, funding allocations, and intellectual property decisions. Token holders control the fate of IP created from community-sponsored research through transparent, community-driven processes.
  • $CURES Token Utility and governance token with a total supply of 100,000,000 tokens. Enables community members to vote on DAO actions and participate in research governance. Allocates 20% to core team (with vesting), 40% to treasury reserves, 15% to community auction, 10% to future token sales, 7% to service providers, 7% to community incentives, and 1% to airdrops.
  • Yeast Drug Repurposing Platform Scientific research platform that leverages Saccharomyces cerevisiae (baker's yeast) as a model organism for high-throughput drug repurposing screens. Partner laboratory Perlara conducts screening against an 8,400-compound TargetMol library to identify existing drugs, nutraceuticals, and supplements with therapeutic potential for rare genetic diseases. Has prospectively identified nearly 800 inherited metabolic diseases (8% of all known rare diseases) caused by loss-of-function mutations in evolutionarily conserved genes.
  • AARS2 Drug Repurposing Project Pilot research project focused on identifying drug repurposing candidates for AARS2 deficiency (Progressive Leukoencephalopathy with Ovarian Failure) using yeast-patient avatars. Screens approximately 8,500 repurposable compounds to find treatments for rare kiddos affected by this mitochondrial disease. Funded through $1.77 million in community crowdfunding.

Quantifiable outcome

  • 95% of 10,000+ rare diseases have no approved treatment, representing massive unmet need
  • +4 more outcomes

Companies that use Curetopia

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Curetopia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Curetopia partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major and minor.

  • CureARS FoundationcoreStrategic or Co-development Partner · 9 December 2024CureARS Foundation is the patient community organization for the AARS2 project. The foundation represents families affected by aminoacyl-tRNA synthetase (ARS) diseases and is ready to spread word about research results to their micro-communities and organize rapid 1-to-N clinical testing in affected children.
  • Perlara PBCcoreTechnology or IntegrationPerlara PBC is Curetopia's primary research partner and yeast-screening laboratory. Founded in 2014 as the world's first biotech Public Benefit Corporation, Perlara conducts high-throughput drug repurposing screens using yeast-patient avatars. Curetopia's AARS2 project is conducted at Perlara's laboratory in Alameda, CA, and builds on Perlara's decade of experience with yeast-powered drug discovery.
  • BIO ProtocolcoreGTM or Marketing PartnerBIO Protocol is a DeSci Funding & Liquidity Protocol that provides support with tokenomics design, DAO formation, legal/regulatory advisory, and Web3 technology infrastructure. BIO received 7% of $CURES token supply as service provider compensation. BIO Protocol's launchpad hosted Curetopia's community auction on Solana.
  • CombinedBRAINmajorStrategic or Co-development PartnerCombinedBRAIN (CB) is an umbrella foundation with 120+ neurodevelopmental disorder (NDD) rare disease community affiliates that share common research infrastructure including a biobank and a network of responsive clinicians willing to test drug repurposing candidates in collaboration with affected families. Curetopia is in active discussions to scale up drug repurposing for all rare disease communities through this partnership.
  • Unravel BiosciencesmajorStrategic or Co-development PartnerUnravel Biosciences is a Boston-based company that has developed rareSHIFT, a fully decentralized, direct-to-patient drug repurposing protocol involving at-home nasal swab collection, RNAseq gene expression analysis, and computational screening for drug repurposing candidates. Curetopia views Unravel as an ideal investment opportunity and codevelopment partner for rare disease programs.
  • Maggie's PearlminorStrategic or Co-development PartnerMaggie's Pearl is a joint venture between Perlara and a PMM2-CDG family foundation dedicated to advancing epalrestat (discovered through drug repurposing screens) to the global market. The venture culminated in a pivotal clinical trial in pediatric PMM2-CDG patients. This represents a model for how Curetopia-funded research could be commercialized.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Curetopia competitors and assessment

Company assessment

Direct peers

  • VitaDAO: Pioneer longevity BioDAO using a $VITA governance token on Ethereum to fund and govern early-stage research, with on-chain IP via Molecule. The most established direct analogue to Curetopia's BioDAO model, differing by therapeutic area.
  • Unravel Biosciences: Boston-based rare disease drug repurposing company with a decentralized, direct-to-patient rareSHIFT protocol; Curetopia lists Unravel as a codevelopment partner and investment target, making it a tightly overlapping peer.
  • Molecule: DeSci platform that pioneered IP-NFTs and on-chain research funding; Curetopia is already a Molecule ecosystem partner, and the two share the same IP-tokenization infrastructure.
  • Biovista: Commercial drug repurposing firm using systematic biological-data approaches to find new indications, including in rare diseases; comparable to Curetopia on the core repurposing thesis but operates as a traditional B2B services company.
  • Healx: AI-driven drug repurposing company focused on rare diseases; comparable in mission and in repurposing methodology, though Curetopia uses yeast models and decentralized governance while Healx uses in-silico AI and traditional venture backing.
  • BIO Protocol: DeSci launchpad and liquidity protocol that incubated Curetopia and hosted its community auction. Closely comparable as the funding-and-launch infrastructure layer for BioDAOs.
  • ValleyDAO: DeSci DAO funding longevity and age-related disease research via IP-NFTs and token-based governance; another direct structural analogue operating in the BioDAO category.
  • AthenaDAO: BioDAO focused on women's health and longevity research using a token-governed funding model; structurally identical to Curetopia (BioDAO + on-chain research funding) but with a different therapeutic focus.

Others

  • CombinedBRAIN: Umbrella foundation for 120+ neurodevelopmental-disorder rare disease community affiliates that shares biobank and clinician infrastructure with Curetopia; functions as a community-distribution partner rather than a competitor, but operates in the same rare-disease space.

Broad incumbents

  • Perlara PBC: Curetopia's core research partner and laboratory operator; founded by the same individual, it is the world's first biotech Public Benefit Corporation and runs the yeast-powered drug repurposing platform that Curetopia's pipeline depends on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Curetopia social profiles

Digital presence

Curetopia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curetopia leadership team

Management profile

Number of profiles

Profiles4 records

Curetopia funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curetopia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curetopia

What does Curetopia do?

Curetopia operates as a BioDAO (Biotech Decentralized Autonomous Organization) structured as a Swiss non-profit association that funds and conducts rare disease research through on-chain governance. The organization uses yeast-powered drug repurposing screens (Saccharomyces cerevisiae model organisms) against an 8,400-compound library to identify existing drugs, nutraceuticals, and supplements with therapeutic potential for rare genetic diseases. Community members govern research direction and IP outcomes via the $CURES governance token on Solana.

Is Curetopia a public or private company?

Curetopia is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Curetopia founded?

Curetopia was founded in 2024. It employs 1 to 10 people.

Where is Curetopia based?

Curetopia is headquartered in Zug, Switzerland, in the Europe region.

How does Curetopia make money?

Four revenue lines are on record. Direct-to-Consumer Commercial Spinouts are the primary driver. The others are biopharma Licensing Deals, mission-Aligned Investments and priority Review Voucher (PRV) Value.

Who are Curetopia's main competitors?

Direct peers on record are VitaDAO, Unravel Biosciences, Molecule, Biovista, Healx, BIO Protocol, ValleyDAO and AthenaDAO. CombinedBRAIN is listed as an others. Perlara PBC is listed as a broad incumbent.

Does Curetopia have an API?

No public API is recorded for Curetopia.

What industry is Curetopia in?

Curetopia's product category is Rare Disease Research. Its primary akta.pro industry code is HLAJAKAN, Global Health Research, Evidence & Technical Assistance Organizations, with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarBiotech Community Curetopia Raises $1.77M to Advance Rare Disease Cures with BlockchainCuretopia, a Biotech DAO on Solana, raised $1.77 million to fund drug repurposing for AARS2 Deficiency, a rare disease with no approved therapies. Over 1,000 contributors participated, and two repurposing candidates were identified via yeast-powered screening. The organization plans to file a provisional patent and develop an AI-driven decentralized clinical trial model.Business InsiderBiotech Community Curetopia Raises $1.77M to Advance Rare Disease Cures with BlockchainCuretopia, a Biotech DAO on Solana, raised $1.77 million to fund drug repurposing for AARS2 Deficiency, a rare disease with no approved therapies. Over 1,000 contributors participated, and two repurposing candidates were identified via yeast-powered screening. The organization plans to file a provisional patent and develop an AI-driven decentralized clinical trial model.FinancialContent Business PageBiotech Community Curetopia Raises $1.77M to Advance Rare Disease Cures with BlockchainCuretopia, a Biotech DAO on Solana, raised $1.77 million to fund drug repurposing for AARS2 Deficiency, a rare disease with no approved therapies. Over 1,000 contributors participated, and two repurposing candidates were identified via yeast-powered screening. The organization plans to file a provisional patent and develop an AI-driven decentralized clinical trial model.BioCuretopia Raises $1.77M to Accelerate Rare Disease Cures Using DeSci • BIO ResourcesCuretopia, a Solana-based biotech DAO, raised $1.77M from over 1,000 individual funders to develop treatments for rare diseases. The funding follows a discovery of a potential treatment for AARS2, a fatal rare disease, with proceeds flowing back to the DAO. The DAO aims to accelerate drug discovery for over 10,000 rare diseases using decentralized science.